Ken Griffin Enlivex Therapeutics Ltd. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$1.27 - $4.31 $20,193 - $68,529	15,900 Added 7950.0%	16,100 $22,000
Q1 2024 May 15, 2024	SELL	$2.54 - $4.3 $18,796 - $31,820	-7,400 Reduced 97.37%	200 $0
Q4 2023 Feb 14, 2024	BUY	$1.29 - $2.92 $7,869 - $17,812	6,100 Added 406.67%	7,600 $20,000
Q3 2023 Nov 14, 2023	SELL	$1.46 - $2.97 $6,278 - $12,771	-4,300 Reduced 74.14%	1,500 $2,000
Q2 2023 Aug 14, 2023	SELL	$2.51 - $3.71 $14,055 - $20,776	-5,600 Reduced 49.12%	5,800 $15,000
Q1 2023 May 15, 2023	SELL	$3.41 - $4.55 $226,083 - $301,665	-66,300 Reduced 85.33%	11,400 $41,000
Q4 2022 Feb 14, 2023	SELL	$3.74 - $4.81 $684,420 - $880,229	-183,000 Reduced 70.2%	77,700 $306,000
Q3 2022 Nov 14, 2022	BUY	$4.11 - $5.87 $998,730 - $1.43 Million	243,000 Added 1372.88%	260,700 $1.11 Million

2.1M

16.1K

3.4K

Ticker ENLV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,403,200
Market Cap $28.9M
Description
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.